News for Ironwood Pharmaceuticals, Inc. (IRWD)

Key Highlights for Investors:\n Ironwood Pharmaceuticals (IRWD) faces a setback with FDA requiring another phase 3 trial for apraglutide. The stock dipped 31%,

Ironwood Pharmaceuticals (IRWD) has been downgraded by Craig-Hallum from \

Jefferies has revised its rating for Ironwood Pharmaceuticals (IRWD), downgrading the stock from Buy to Hold. This decision comes in the wake of the U.S. Food a

Ironwood Pharmaceuticals (IRWD) experienced a significant drop in its stock price, falling by 31% to $0.66 during midday trading. The sharp decline came after C

Ironwood Pharmaceuticals (IRWD) faces increased financial challenges as Leerink analyst Faisal Khurshid adjusted the company's price target downward from $3 to

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday. The Dow traded up 0.43% to 40,384.20 while t...

Key Takeaways: Ironwood Pharmaceuticals (IRWD) is assessing strategic paths following a regulatory setback. The FDA's requirement for an additional Phase

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 2% on Monday. The Dow traded up 0.99% to 40,610.00 while the NASDAQ gained 2.0...

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living wi

Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with apraglutide for short bowel...

On March 13, 2025, Sarissa Capital Management LP (Trades, Portfolio) executed a significant transaction involving Innoviva Inc. The firm reduced its holdings by

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Ironwood Pharmaceuticals, Inc.

Net Sales: $916 million for the full year 2024.LINZESS US Net Sales: $223 million in Q4 2024 and $916 million for the full year.Prescription Demand Growth: 11%

Feb 27, 2025 / 01:30PM GMTOperator My name is Kathleen and I will be your conference operator today. At this time I would like to welcome everyone to the Ironwo

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsGreg Martini - Chief Financial...

Ironwood (IRWD) delivered earnings and revenue surprises of -80% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $90.55 million for Q4 2024, missing the estimated $93.82 million.Earnings Per Share (EPS): $0.02 for Q4 2024, missing the estimated $0.07.Full-Year Re

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living wi

Ironwood Pharmaceuticals Inc (IRWD) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $93.82 million, and th